Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease
|
|
- Theodora Simpson
- 5 years ago
- Views:
Transcription
1 Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease Iana I. Simova, MD; Stefan V. Denchev, PhD; Simeon I. Dimitrov, PhD Clinic of Cardiology, University Hospital Alexandrovska, Sofia, Bulgaria Address for correspondence: Iana I. Simova, MD Clinic of Cardiology University Hospital Alexandrovska Georgi Sofiiski 1 Sofia 1431, Bulgaria ianahr@yahoo.com Background: Flow-mediated dilatation (FMD) of the brachial artery is a method capable of detecting endothelium dysfunction. Statins are generally consent drugs for reducing cardiovascular morbidity and mortality and are shown to improve the systemic endothelial function. Hypothesis: The aim of our study was to assess the endothelial function using FMD of the brachial artery in patients with different degrees of coronary artery stenosis with respect to their treatment with statins. Methods: We evaluated the FMD of 221 patients with coronary arteriography performed, of whom 99 (44.8%) were receiving statins and 122 (55.2%) were not receiving statins. Results: We did not find a statistically significant difference in the FMD values between the patients with and without a statin treatment: 5.57 ± 5.68 and 4.69 ± 4.48, respectively, P =.581. In the subgroup of patients without angiographically visible coronary artery stenoses or with stenoses < 20% (86 patients), patients undergoing statin treatment had a significantly better endothelial function compared to patients without such a treatment: FMD 9.24±6.87 and 6.50±4.51, respectively, P =.047. Conclusions: FMD could not distinguish between the patients who were treated with statin and those not treated with statins with the same demographic, clinical, and angiographic characteristics. The only exception was in the group of patients with a minor coronary disease. had a more pronounced effect in the earlier stages of coronary atherosclerosis. Introduction Some changes in the function of the endothelium are present even in the very early stages of atherosclerosis when no structural impairment in the vessel wall is evident. Flow-mediated vasodilatation of the brachial artery is a method considered capable of detecting the early changes in endothelial function. The method was first described and implemented in clinical practice by Celermajer et al. 1 Statins are generally accepted for reducing cardiovascular morbidity and mortality in coronary artery disease (CAD) patients, and this effect is observed in the patient groups with different levels of baseline low-density lipoprotein (LDL)- cholesterol. 2 They have well-recognized pleotropic effects beside the lipid-lowering action and have been shown to improve the systemic endothelial function in patients with CAD. 3 It is of interest to know how the statin treatment itself, regardless of its direct effects on lipid metabolism, affects the endothelial function in a patient cohort where the level of control of dyslipidemia is not optimal. The aim of our study was to assess the endothelial function using flow-mediated dilatation (FMD) of the brachial artery in patients with different degrees of coronary artery stenosis with respect to treatment with statins. Methods Study Group We investigated 221 patients, admitted to the Clinic of Cardiology, University Hospital Alexandrovska between July 2006 and March These were patients with angina Received: June 29, 2007 Accepted with revision: September 12, 2007 pectoris or an already established CAD, with positive exercise stress test. Every patient underwent coronary arteriography (CAG) as a part of his/her diagnostic evaluation. The demographic characteristics and distribution of risk factors of patients are presented in Table 1. The clinical characteristics with respect to CHD are presented in Table 2. Only 99 patients (44.8%) from the whole group of 221 patients had been on a statin treatment for at least 1 month at the time of investigation. Only 23 patients (18.9%) of those not receiving a statin treatment (122 patients) did not have dyslipidemia as defined by the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice total cholesterol 4.5 mmol/l and LDLcholesterol 2.5 mmol/l. 4 This means that 81.1% of the patients in our group with an already known dyslipidemia were untreated. On the other hand, only 10 patients (10.1%) among the patients receiving a statin for at least 1 month (99 patients) had reached their target values. The statin most commonly used in the study was lovastatin (54%), with a mean dose of 36.4 mg (±8.2), followed by atorvastatin (30%), mean dose 13.8 mg (±3.5), and simvastatin (16%), mean dose 27.5 mg (±6.3). Patients were included regardless of their sex and age. Patients who were admitted in our clinic for diagnostic evaluation and treatment who had data available regarding their use of statin were considered eligible. Patients were included in groups with a statin treatment if they had been Clin. Cardiol. 32, 4, (2009) 193
2 Clinical Investigations continued Table 1. Demographic Characteristics of the Patients and Distribution of Risk Factors Clinical Variable Unit Distribution All cases n = 221 (100%) Female gender Number (percent) 106 (48%) Age (years) Mean (± standard 59.6 (±9.6) deviation) Body mass index (BMI) Mean (± standard (±4.01) deviation) Arterial hypertension Number (percent) 188 (85.1%) Diabetes mellitus Number (percent) 51 (23.1%) Current smokers Number (percent) 36 (16.3%) Past smokers Number (percent) 119 (53.8%) Table 2. Clinical Characteristics of the Patients Clinical Variable Unit Distribution All cases n = 221 (100%) Angina pectoris Number (percent) 183 (82.8%) History of myocardial Number (percent) 84 (38%) infarction (MI) Duration of statin Mean (± standard 8.5 (±3.1) treatment (months) deviation) Patients were considered with a history of myocardial infarction (MI), if they had a MI for at least one month before the inclusion. Patients with a more recent MI had been excluded. The mean time elapsed from MI was 15.6±6.7months. receiving this kind of treatment for at least 1 month. Patients presenting with acute coronary syndrome, and patients with hemodynamically significant valvular disease, and patients with previously performed coronary interventions or surgical revascularization were excluded. Ethics All patients signed an informed consent for FMD measurement. The investigation protocol was approved by the local ethical committee. Flow-Mediated Brachial Artery Dilatation FMD was accomplished according to the guidelines for the ultrasound assessment of endothelial-dependent flowmediated vasodilation of the brachial artery. 5 The inter- and intraobserver variability of the method was evaluated on a sample of 40 patients with a correlation coefficient > 0.92, p < FMD was done in the morning between 7 and 9 AM. In the evening prior to the study, the patient was asked to refrain from eating or drinking alcoholic beverages, and to avoid smoking after 8 PM. Long-acting nitrates were not allowed for 24 hours. On the morning before the study, the patient was asked not to consume anything but water, not to smoke, to postpone taking his/her prescribed medication until after the study, and to refrain from any vigorous physical activity. The investigation started with the taking of the blood pressure on the dominant arm after a 15-minute rest in a quiet and temperate room. Then the cuff of the sphygmomanometer was placed on the forearm of the same arm with the patient in a supine position, and a longitudinal image of the brachial artery was obtained with optimal visualization of the intima using a linear array transducer 3 11 MHz and a Sonos 5500 echocardiograph. A 5- to 10 second recording on a video cassette recorder (VCR) of the baseline state of the brachial artery was done. The cuff was inflated to a pressure of 200 mm Hg or 50 mm Hg above the systolic arterial pressure of the given patient, whichever was higher, and maintained as such for 5 minutes. A new recording on the VCR was done during the last 30 seconds of the ischemic phase (with cuff inflated) and then 120 seconds after the cuff deflation. The whole image was electrocardiogram (ECG)-gated. Measurement The analysis was made off-line. Two parameters were taken: the baseline diameter of the brachial artery and the maximum postischemic stimulus diameter of the artery. All measurements were done in the end-diastole (the beginning of the R on the ECG) from the endothelial to the endothelial surface along a line perpendicular to the artery s long axis. The FMD was measured in terms of percentage and derived by the formula given here: FMD (%) = ([postischemic diameter of the brachial artery-baseline diameter] / baseline diameter) 100. Statistics Continuous variables were presented as mean ± standard deviation. Categorical variables were presented in terms of percentage. The distribution of the data within groups was tested with the Kolmogorov Smirnov test. With normal distribution an independent samples t test to compare means for FMD was used. When the distribution was not normal the Mann-Whitney U test was used. The distribution of risk factors and clinical variables between the groups was compared with the chi-square test. A two-tailed p value <.05 was considered significant. All tests were performed with SPSS 13 for Windows (SPSS, Inc., Chicago, IL). 194 Clin. Cardiol. 32, 4, (2009)
3 Table 3. Distribution of Patients According to Statin Treatment and Percent Stenosis of the Coronary Arteries 1 p = No Treatment Statin Treatment 1 %stenosis n= 122 n = 99 <20% % % Mean FMD ,50 9, p = Error bar.: 95.00% CI 5.00 Mean FMD ,693 5,566 Error bar.: 95.00% CI Figure 1. Mean FMD values in patients without statin treatment and those with such treatment for the whole study population. CI = confidence interval; FMD = flow-mediated dilatation. Results Patients The 221 patients were divided into groups according to their treatment status with statins and the degree of coronary artery stenosis (Table 3). The mean FMD values for the entire groups of statintreated (99 patients) and statin-untreated (122 patients) patients were not significantly different (Figure 1). If patients with coronary artery stenoses < 20% were divided into groups according to their statin treatment (33 patients) or with no statin treatment (53 patients), and the mean values for FMD were compared for the two groups, there would be a statistically significant difference in the FMD values indicating a better endothelial function for those patients receiving this type of medication (Figure 2). The risk factors for atherosclerosis, the presence of angina pectoris, and treatment with ACE inhibitors or calcium channel blockers, which could affect the values for the FMD, were equally distributed between the groups treated and not treated with statins for the entire group of patients and for the subgroup with stenosis < 20% (Tables 4 and 5). There was one exception patients with a previous Figure 2. Mean FMD values in patients without statin treatment and those with such treatment for the subgroup with stenoses < 20%. CI = confidence interval; FMD = flowmediated dilatation. myocardial infarction (MI) were more likely to be treated with statins than those without MI. In the 110 patients with stenoses < 50% on CAG, including the former group, there was no statistically significant difference in the endothelial function between the patients receiving (44 patients) and those not receiving (66 patients) a statin (Figure 3). When patients presented with a significant ( 50%) coronary artery stenosis, there again was not much of a significant difference in endothelium-dependent vasodilatation between the group with (55 patients) and those without (56 patients) statin treatment (Figure 4). Discussion Dyslipidemia is a well-known major atherosclerotic risk factor. Guidelines relevant for the European practice recommend that the total cholesterol and LDL-cholesterol should be reduced to a level below 5 mmol/l and 3 mmol/l, respectively, with more stringent goals of total cholesterol < 4.5 mmol/l and LDL-cholesterol < 2.5 mmol/l for patients with cardiovascular disease and diabetes. 4 However the implication of these recommendations is far from optimal, which leaves a major part of patients with dyslipidemia undertreated both in Europe and in the United States. According to different surveys that included a large number of patients, 7 the NCEP/ATP III lipid goal 8 has been achieved only in a minority of the study group, and the proportion of patients receiving statin treatment also varies within individual countries. 9 Only 44.8% in our study group of 221 patients were receiving statin treatment at the time of investigation, and only 10.1% of them had achieved the target values. Clin. Cardiol. 32, 4, (2009) 195
4 Clinical Investigations continued Table 4. Distribution of Risk Factors and Clinical Characteristics for the Whole Group of Patients According to a Statin Treatment Status Clinical Variable Without Statin Treatment With Statin Treatment Significance Number 122 (55.2%) 99 (44.8%) Female gender n (%) 51 (41.8%) 55 (55.5%) Age mean ± SD (±9.05) (±9.61) BMI mean ± SD (±4.25) (±3.71) Arterial hypertension n (%) 106 (86.9%) 82 (82.8%) Diabetes mellitus n (%) 26 (21.3%) 25 (25.3%) Active smokers n (%) 19 (15.6%) 17 (17.2%) Former smokers n (%) 62 (50.8%) 57 (57.6%) Angina pectoris n (%) 105 (86.1%) 78 (78.8%) Myocardial infarction n (%) 36 (29.5%) 48 (48.5%) 4 Treatment with ACE inhibitor n (%) 105 (86.1%) 91 (91.9%) Treatment with calcium channel blockers n (%) 30 (24.6%) 24 (24.2%) Table 5. Distribution of Risk Factors and Clinical Characteristics in Patients Without Visible Coronary Artery Lesions on CAG According to Statin Treatment Status Clinical Variable Without Statin Treatment With Statin Treatment Significance Number 53 (61.6%) 33 (38.4%) Female gender n (%) 36 (67.9%) 27 (81.8%) Age mean ± SD 61.7 (±9.47) (±8.94) BMI mean ± SD (±4.5) (±3.22) Arterial hypertension n (%) 46 (86.8%) 29 (87.9%) Diabetes mellitus n (%) 10 (18.9%) 5 (15.2%) Active smokers n (%) 6 (11.3%) 8 (24.2%) Former smokers n (%) 16 (30.2%) 14 (42.4%) Angina pectoris n (%) 48 (90.6%) 31 (93.9%) Myocardial infarction n (%) 2 (3.8%) 5 (15.2%) Treatment with ACE inhibitor n (%) 48 (90.6%) 30 (90.9%) Treatment with calcium channel blockers n (%) 15 (28.3%) 8 (24.2%) This reflects the undertreatment in such patients who are generally considered as candidates for statin therapy. The correlation between statin treatment and endothelial function has been a subject of interest for many investigators. A REVERSAL trial substudy evaluated the effect of intensive and moderate cholesterol lowering with statins in CAD patients with low LDL-cholesterol, and it has been proven to effect a significant improvement in endothelial function during the statin treatment. 10 Our study showed that in a group of patients with angina pectoris or with an already established CAD, those receiving a statin treatment did not have a better endothelial function compared to patients without a statin treatment. It must be noted, however, that only 10.1% of our patients had achieved the target lipid levels at the time of investigation. That means, we assume, that the pleiotropic effects of statins alone are not enough to improve the endothelial function. Another possible explanation could be that the duration of 196 Clin. Cardiol. 32, 4, (2009)
5 Mean FMD p = ,426 8,413 Error bar: 95.00% CI Figure 3. Mean FMD values in patients without statin treatment and those with such treatment for the subgroup with stenoses < 50%. Mean FMD p = ,649 3,288 Error bar: 95.00% CI Figure 4. Mean FMD values in patients without statin treatment and those with such treatment for the subgroup with stenosis 50%. CI = confidence interval; FMD = flow-mediated dilatation. statin treatment was not long enough for the potentially beneficial effect of statins on endothelial function to take place. On the other hand, patients in the statin group might have had a worse baseline FMD, which had been improved after statins had been initiated. However, the endothelial function was significantly better in the subgroup of patients without angiographically visible coronary stenoses or with stenoses < 20% when the patients were receiving a statin. There was not much of a statistically significant difference in the distribution of demographic and clinical variables between these two groups of patients, which could have influenced the brachial artery response and, therefore, the greater FMD values could possibly be attributed to the statin treatment itself. TheFMDvaluesweredistinctlydecreasedinthegroup of patients with angiographically significant CAD, but again regardless of the statin treatment status. Of interest is that in our study group, the beneficial effect of statins on endothelial function was only evident in patients with minor CAD. One possible explanation could be that the pleiotropic and anti-inflammatory effects of statins could be more pronounced when the endothelium is not severely damaged, as it is in those cases with earlier atherosclerosic changes in coronary arteries. Another explanation could be that a beneficial effect on endothelial function was present during statin treatment in patients with significant coronary stenoses, but the methods used in detecting them, the FMD was not sensitive enough. Our results are in contradiction to the findings of Vogel et al, 10 but it should be noted that the patient group in the REVERSAL trial has a low LDL-cholesterol level at baseline and that most of our patients do not reach their target lipid levels even during a statin treatment. In future endeavors, we contemplate examining meticulously the interaction between dyslipidemia, statin treatment, and the endothelial function including examining larger patient cohorts as well as prospectively following patient groups, randomized to statin or placebo. In our opinion, it is of importance to investigate the effects of statins with respect to the patients gender and the presence or absence of diabetes mellitus. Our study was retrospective and observational, therefore a selection bias cannot be excluded. As already mentioned, the group in which the target lipid goals were reached was of a relatively small size, and we did not have information about the baseline FMD of the patients. Conclusion On the basis of the results obtained in our study, we conclude that FMD cannot distinguish between patients treated with statins and those not treated with statins using the same demographic, clinical, and angiographic characteristics. An exception is seen in the group of patients with minor coronary disease. has a more pronounced effect in the earlier stages of coronary atherosclerosis. References 1. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340: Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: Jarvisalo MJ, Toikka JO, Vasankari T, et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis. 1999;147: Clin. Cardiol. 32, 4, (2009) 197
6 Clinical Investigations continued 4. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2003;10:S1 S Corretti M, Anderson T, Benjamin E, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. A report of the international brachial artery reactivity task force. J Am Coll Cardiol. 2002;39: Simova I, Nossikov A, Denchev S. Interobserver and intraobserver variability of flow mediated vasodilatation of the brachial artery. Echocardiography. 2008;25: Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicentre study to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160: Expert Panel on Detection, Evaluation, and Treatment High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285: EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22: Vogel RA, Nissen AE, Weiss RJ. Endothelial function, low-density lipoprotein, and moderate and intensive cholesterol lowering in coronary artery disease: a REVERSAL trial substudy. J Am Coll Cardiol. 2005;45:412A, Abstract Clin. Cardiol. 32, 4, (2009)
Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationHow to detect early atherosclerosis ; focusing on techniques
How to detect early atherosclerosis ; focusing on techniques Jang-Ho Bae, MD., PhD. Heart Center Konyang University Hospital Daejeon city, S. Korea Surrogates for Atherosclerosis Measures of endothelial
More informationA study of brachial artery flow mediated dilatation and carotid intima media thickness in subjects having risk factors for coronary artery disease
International Journal of Advances in Medicine http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20171037 A study of brachial
More informationThe EUROASPIRE surveys: lessons learned in cardiovascular disease prevention
Brief Report The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention Kornelia Kotseva 1,2 ; on behalf of the EUROASPIRE Investigators 1 National Heart & Lung Institute, Imperial College
More informationPrognostic Value of Brachial Artery Endothelial Function and Wall Thickness
Journal of the American College of Cardiology Vol. 46, No. 6, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.070
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationSTATINS FOR PAD Long - term prognosis
STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationPreventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform?
Journal of the American College of Cardiology Vol. 41, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00187-6
More informationEndothelial function and left ventricular remodeling in diabetic and non-diabetic patients after acute coronary syndrome
Med Sci Monit, 2011; 17(2): 73-77 PMID: 21278691 WWW.MEDSCIMONIT.COM Clinical Research Received: 2010.05.10 Accepted: 2010.08.09 Published: 2011.02.01 Endothelial function and left ventricular remodeling
More informationHeart Online First, published on March 29, 2005 as /hrt SCIENTIFIC LETTER
Heart Online First, published on March 29, 2005 as 10.1136/hrt.2004.056523 Manuscript ID: HEARTJNL/2004/056523 March 18, 2005 SCIENTIFIC LETTER Effects of HMG-CoA Reductase Inhibition on Endothelial Function
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationThe Impact Of Adiposity And Insulin Resistance On Endothelial Function In Middle-Aged Subjects
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 1 Number 1 The Impact Of Adiposity And Insulin Resistance On Endothelial Function In Middle-Aged Subjects L Zhu, K Liu Citation L Zhu, K
More informationAN EARLY WARNING SYSTEM FOR CARDIOVASCULAR DISEASE
AN EARLY WARNING SYSTEM FOR CARDIOVASCULAR DISEASE Good for your patients. Good for your practice. Using the AngioDefender system to complement your patients care routine enables you to: Improve your patient
More informationImaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006
Imaging Biomarkers: utilisation for the purposes of registration EMEA-EFPIA Workshop on Biomarkers 15 December 2006 Vascular Imaging Technologies Carotid Ultrasound-IMT IVUS-PAV QCA-% stenosis 2 ICH E
More informationRetinal vessel analysis in dyslipidemia: The eye, a window to the body s microcirculation
Project Summary SWISS LIPID RESEARCH AWARD 2017 SPONSORED BY AMGEN Retinal vessel analysis in dyslipidemia: The eye, a window to the body s microcirculation Matthias P. Nägele, M.D. 1, Jens Barthelmes,
More informationThe updated guidelines from the National
BEYOND NCEP ATP III: LESSONS LEARNED AND FUTURE DIRECTIONS * Benjamin J. Ansell, MD, FACP ABSTRACT The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines provide
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationHEART RATE IN PATIENTS WITH CORONARY ARTERY DISEASE IN LATVIA
Inga Balode HEART RATE IN PATIENTS WITH CORONARY ARTERY DISEASE IN LATVIA Summary of the Doctoral Thesis for obtaining the degree of a Doctor of Medicine Speciality Internal Medicine Riga, 2014 Doctoral
More informationAndrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University
CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients
More informationTitle for Paragraph Format Slide
Title for Paragraph Format Slide Presentation Title: Month Date, Year Atherosclerosis A Spectrum of Disease: February 12, 2015 Richard Cameron Padgett, MD Executive Medical Director, OHVI Pt RB Age 38
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationStatin pretreatment and presentation patterns in patients with acute coronary syndromes
Brief Report Page 1 of 5 Statin pretreatment and presentation patterns in patients with acute coronary syndromes Marcelo Trivi, Ruth Henquin, Juan Costabel, Diego Conde Cardiovascular Institute of Buenos
More informationReceived: March 2008; in final form May 2008.
RELATIONSHIP BETWEEN BRACHIAL ARTERY FLOW- MEDIATED DILATION AND CAROTID ARTERY INTIMA MEDIA THICKNESS IN THE MIDDLE-AGED SUBJECTS WITH LOW CARDIOVASCULAR RISK GERMAINE SĂVOIU*, LAVINIA NOVEANU**, O. FIRA-MLADINESCU*,
More informationCorrelation of LV Longitudinal Strain by 2D Speckle Tracking with Cardiovascular risk in Elderly. (A pilot study of EGAT-Echo study.
Correlation of LV Longitudinal Strain by 2D Speckle Tracking with Cardiovascular risk in Elderly. (A pilot study of EGAT-Echo study.) Researcher: Dr. Atthakorn Wutthimanop, MD. Research adviser: Dr.PrinVathesathokit,
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationAutonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors
Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationShort Communication Effect of Atorvastatin on E.C.G changes in Coronary artery disease Singh H 1, Gupta A 2, Bajaj VK 3, Gill BS 4, Singh J 5
Short Communication Effect of Atorvastatin on E.C.G changes in Coronary artery disease Singh H 1, Gupta A 2, Bajaj VK 3, Gill BS 4, Singh J 5 1 Dr. Harmanjit Singh Senior resident, Pharmacology PGIMER,
More informationCoronary artery disease (CAD) risk factors
Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes
More informationCho et al., 2009 Journal of Cardiology (2009), 54:
Endothelial Dysfunction, Increased Carotid Artery Intima-media Thickness and Pulse Wave Velocity, and Increased Level of Inflammatory Markers are Associated with Variant Angina Cho et al., 2009 Journal
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationArterial Age and Shift Work
340 Arterial Age and Shift Work Ioana Mozos 1*, Liliana Filimon 2 1 Department of Functional Sciences, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania 2 Department of Occupational
More informationEndothelial dysfunction and the role of hypertension in Nepalese subjects with major coronary risk factors
Original Article Endothelial dysfunction and the role of hypertension in Nepalese subjects with major coronary risk factors Mani Prasad Gautam, 1 Samir Gautam, 2 Usha Ghimire, 3 Sogunuru Guruprasad, 4
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationBy Graham C. Wong, MD; and Christian Constance, MD. therapy in reducing long-term cardiovascular
Lipid-Lowering Therapy For Acute Coronary Syndromes There is a large amount of evidence that supports the early use of statins in the treatment of acute coronary syndromes. The anti-inflammatory, anti-thrombotic
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationSimvastatin With or Without Ezetimibe in Familial Hypercholesterolemia
Simvastatin With or Without Ezetimibe in Familial Hypercholesterolemia The trial ClinicalTrials.gov number: NCT00552097 John J.P. Kastelein, MD, PhD* Department of Vascular Medicine Academic Medical Center
More informationGender-Based and Age-Related Peculiarities of Lipid Metabolism in Chronic Heart Failure Secondary to Overweight and Obesity
71 P.P.Bidzilya Gender-Based and Age-Related Peculiarities of Lipid Metabolism in Chronic Heart Failure Secondary to Overweight and Obesity Zaporizhzhya State Medical University, Zaporizhzhya, Ukraine
More informationLow fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease
(2002) 16, 837 841 & 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Low fractional diastolic pressure in the ascending aorta increased the risk
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationMPS and Calcium Score in asymptomatic patient F. Mut, J. Vitola
MPS and Calcium Score in asymptomatic patient F. Mut, J. Vitola Nuclear Medicine Service, Asociacion Española Montevideo, Uruguay Quanta Diagnostico Nuclear Curitiba, Brazil Clinical history Male 63 y.o.,
More informationSTABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationClinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease
Cronicon OPEN ACCESS EC NEUROLOGY Research Article Clinical Features and Subtypes of Ischemic Stroke Associated with Peripheral Arterial Disease Jin Ok Kim, Hyung-IL Kim, Jae Guk Kim, Hanna Choi, Sung-Yeon
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationMedical management of abdominal aortic aneurysms
Medical management of abdominal aortic aneurysms Definition of AAA - Generally a 50% increase in native vessel diameter - Diameter 3 cm - Relative measures compared with nondiseased aortic segments less
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationFive chapters 1. What is CVD prevention 2. Why is CVD prevention needed 3. Who needs CVD prevention 4. How is CVD prevention applied 5. Where should CVD prevention be offered Shorter, more adapted to clinical
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationLifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular
More informationCurrent and Future Imaging Trends in Risk Stratification for CAD
Current and Future Imaging Trends in Risk Stratification for CAD Brian P. Griffin, MD FACC Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Disclosures: None Introduction
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationMEDICAL POLICY SUBJECT: CORONARY CALCIUM SCORING
MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationAmerican Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease
American Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease AMWA is a leader in its dedication to educating all physicians and their patients about heart disease,
More informationAcute Effects of Vasoactive Drug Treatment on Brachial Artery Reactivity
Journal of the American College of Cardiology Vol. 40, No. 4, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02034-X
More informationStudy of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri
Original Research Article Study of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri P. Sasikumar * Department of General Medicine, Govt.
More informationThe role of statins in patients with arterial hypertension
Invited review The role of statins in patients with arterial hypertension Trygve B. Tjugen 1, Sigrun Halvorsen 1, Reidar Bjørnerheim 1, Sverre E. Kjeldsen 1, 2 1University of Oslo, Department of Cardiology,
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationMandana Nikpour 1,2, Murray B Urowitz 1*, Dominique Ibanez 1, Paula J Harvey 3 and Dafna D Gladman 1. Abstract
RESEARCH ARTICLE Open Access Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationBe Still My Beating Heart!
030-Coronary Disease 1/13/04 12:21 PM Page 30 Be Still My Beating Heart! An Update on Coronary Disease Heart disease has long been considered a male health problem, because men are affected at an earlier
More informationNearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III
... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated
More informationBrachial artery hyperemic blood flow velocities are related to carotid atherosclerosis Susann J. Järhult, Johan Sundström and Lars Lind
Clin Physiol Funct Imaging (29) doi: 1.1111/j.1475-97X.29.879.x Brachial artery hyperemic blood flow velocities are related to carotid atherosclerosis Susann J. Järhult, Johan Sundström and Lars Lind Department
More informationImaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD
Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD Hein J. Verberne Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands International Conference
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationRepeat ischaemic heart disease audit of primary care patients ( ): Comparisons by age, sex and ethnic group
Repeat ischaemic heart disease audit of primary care patients (2002-2003): Comparisons by age, sex and ethnic group Baseline-repeat ischaemic heart disease audit of primary care patients: a comparison
More informationConduit Artery Constriction Mediated by Low Flow
Journal of the American College of Cardiology Vol. 51, No. 20, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.01.049
More informationFFR vs icecg in Coronary Bifurcations FIESTA ClinicalTrials.gov Identifier: NCT
FFR vs icecg in Coronary Bifurcations FIESTA ClinicalTrials.gov Identifier: NCT01724957 Dobrin Vassilev MD, PhD Assoc. Prof. in Cardiology Head Cardiology Clinic, Alexandrovska University Hospital Medical
More informationLDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC
Am J Cardiol (2004);94:729-32 Relation of degree of physical activity to coronary artery calcium score in asymptomatic individuals with multiple metabolic risk factors M. Y. Desai, et al. Ciccarone Preventive
More informationARBITER 6-HALTS HDL And LDL Treatment Strategies
ARBITER 6-HALTS HDL And LDL Treatment Strategies Extended-Release Niacin or Ezetimibe and Carotid Intima Media Thickness Allen J. Taylor, M.D. Todd C. Villines, M.D. Eric J. Stanek, Pharm.D. Patrick J.
More informationEpidemiologic and clinical comparison of renal artery stenosis in black patients and white patients
ORIGINAL ARTICLES Epidemiologic and clinical comparison of renal artery stenosis in black patients and white patients Andrew C. Novick, MD, Safwat Zald, MD, David Goldfarb, MD, and Ernest E. Hodge, MD,
More informationNEW GUIDELINES FOR CHOLESTEROL
NEW GUIDELINES FOR CHOLESTEROL NEW CHOLESTEROL GUIDELINES 2013 Recently updated guidelines for the treatment of high blood cholesterol levels is a major update since 2002. The news media have trumpeted
More informationSecondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION
Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION Dr Kornelia Kotseva National Heart & Lung Insitute Imperial College London, UK on behalf of all investigators participating
More informationCoronary heart disease (CHD) has. Clearfield The National Cholesterol Education Program Adult Treatment Panel III guidelines
the osteopathic physician. The treatment approach involves therapeutic lifestyle changes with diet, exercise, and weight loss. It requires regular, careful monitoring of serum cholesterol levels. The new
More informationMaria Angela S. Cruz-Anacleto, MD
Maria Angela S. Cruz-Anacleto, MD 57/Female Menopausal Non-HTN, non-dm Hypothyroid (s/p RAI 1997) Levothyroxine 100 ug OD 5 Months PTA Chest discomfort Stress Echocardiography 5 Months PTA Chest discomfort
More informationLandmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549
2017 Update of ESC/EAS Task Force on Practical Clinical Guidance for PCSK9 inhibition in Patients with Atherosclerotic Cardiovascular Disease or in Familial Hypercholesterolaemia Cardiovascular Outcomes
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationIdentification of subjects at high risk for cardiovascular disease
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet
More informationManagement of stable CAD FFR guided therapy: the new gold standard
Management of stable CAD FFR guided therapy: the new gold standard Suleiman Kharabsheh, MD Director; CCU, Telemetry and CHU Associate professor of Cardiology, Alfaisal Univ. KFHI - KFSHRC Should patients
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More information